|
[9005411.] رقم البحث : 9005411 - |
|
ASSESSMENT OF PENTOXIFYLLINE EFFECTS ON LIVER STEATOSIS UTILIZING DIXON-BASED MRI TECHNIQUE; RANDOMIZED CONTROLLED STUDY / تقييم تأثيرات البنتوكسيفيلين على تنكس الكبد الدهنى باستخدام تقنية التصوير بالرنين المغناطيسي القائمة على ديكسون. دراسة معشاة ذات شواهد |
| |
قطاع الدراسات الصيدلية / الصيدلة الأكلينيكية |
| تخصص البحث : الصيدلة الأكلينيكية |
| |
Bulletin of Pharmaceutical sciences / |
| |
سارة يوسف محمد ( Sarahyousef30@yahoo.com - ) |
| |
د/ أسماء السيد - مؤلف رئيسي |
| |
الصيدلة الإكلينيكية |
| |
Background: Pentoxifylline (PTX) has been proven to reduce hepatic steatosis in animal models; however, data regarding its safety and efficacy in type-2 diabetics (T2D) with nonalcoholic fatty liver disease (NAFLD) are rare. Aim: Determine the effects of PTX in reducing liver fat content (LFC; %) in T2D patients with NAFLD in various disease states. Methods: 187 T2D subjects with NAFLD were randomized to receive either Pentoxifylline 800 mg (PTX group) or standard T2D care only (control group) for 24 weeks. The primary outcomes included changes in LFC (%) as measured by magnetic resonance imaging-derived proton density fat-fraction technique (MRI-PDFF) and the calculation of a fibrosis score (NFS). Results: PTX significantly reduced LFC (%) more than the control group (-8.18 vs. -1.87; P< 0.0001). Only the PTX group significantly reduced the NFS score (-1.16; P<0.0001). The PTX group showed significant LFC changes in liver segments II (-9.77; P< 0.0001), IVb (-9.51; P< 0.0001), and VI (-9.13; P< 0.0001); however, the control group achieved significant LFC changes in liver segments III (-2.57; P= 0.02) and VI (-2.22; P= 0.04). In subgroup analysis, PTX showed comparable efficacy in decreasing LFC in different fibrosis scores, gender, and BMI categories. However, Patients with severe steatosis grade (LFC>22.1%) (-10.55%; P=0.001) and HbA1c levels > 7.5% (-8.75%; P= 0.015) achieved significantly higher LFC reductions than other steatosis grades and HbA1c categories. Conclusion: PTX presented a similar efficacy profile in reducing LFC in different fibrosis scores, genders, and BMI categories, while patients with severe steatosis grade and HbA1c > 7.5% achieved higher LFC reductions. |
| |
 Download Paper |
تسجيل دخول 
